Preferences for vaccines against children’s diarrheal illness among mothers in Poland and Hungary

Poulos, Christine; Standaert, Baudouin; Sloesen, Brigitte; Stryjewska, Izabella; Janitsary, Anna; Hauber, A. Brett

doi:10.1016/j.vaccine.2018.08.001

Cited by 14 publications

(12 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, this is the first study designed to comprehensively assess US adult preferences for HZ vaccines. Other studies, conducted on either general or specific (other than HZ) vaccine preferences among adults, have also shown that VE and OOP cost are key factors in vaccination decisionmaking [29][30][31][32][33][34][35][36][37]. Not all DCE studies have considered the same set of vaccine attributes.…”

Section: Discussionmentioning

confidence: 99%

Preferences for herpes zoster vaccination among adults aged 50 years and older in the United States: results from a discrete choice experiment

Patterson¹,

Myers

Stewart

et al. 2021

Expert Review of Vaccines

Self Cite

View full text Add to dashboard Cite

Background: Most adults, and disproportionately fewer African-Americans, have not received herpes zoster (HZ) vaccination despite current recommendations. This study (GSK study identifiers: 208677/HO-17-18066) assessed HZ vaccination preferences among adults aged ≥ 50 years. Research design and methods: In this discrete choice experiment, respondents chose among a 'no vaccine' option and two HZ vaccine profiles, characterized by seven attributes, in a series of choice questions. Random-parameters logit results were used to predict likely vaccine uptake. Subgroup and latent class analysis of African-American's preferences were performed. Results: The preference weight for choosing HZ vaccines over no vaccine was statistically significant among the 1,454 respondents (71.9% whites; 25.2% African-Americans). Out-of-pocket (OOP) cost and vaccine effectiveness (VE) were the most important attributes. The African-American and the non-African-American subgroups had statistically significant differences in preferences (χ 2 = 59.91, p < 0.001), mainly driven by OOP cost and VE. Latent class analysis identified three groups of African-American respondents with systematically different preferences; two comprised likely-vaccinators, with one being more cost sensitive at lower price thresholds, and one likely non-vaccinators. Conclusions: For all respondents, HZ vaccine choices were most sensitive to total OOP cost, followed by VE.

show abstract

Section: Discussionmentioning

confidence: 99%

Preferences for herpes zoster vaccination among adults aged 50 years and older in the United States: results from a discrete choice experiment

Patterson¹,

Myers

Stewart

et al. 2021

Expert Review of Vaccines

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similar surveys conducted in European countries have also shown that out-of-pocket expenses or vaccine cost, vaccine effectiveness, duration of protection and frequency of severe adverse effects were factors influencing parents when deciding about vaccination against RV for their children. 31,44 A survey of parents from Canada revealed that the main reasons why parents who had positive intentions yet did not have their child vaccinated were that they believed the child was receiving enough vaccines, that RV vaccine was not useful and RV vaccine was not included in the free public vaccination program. 32 Providing clarity on how to have access to the vaccine and its easy administration, the early successes of RV vaccination program introduction in 97 NIPs as of 2018 and its cost could potentially contribute to increasing the RV vaccination rate.…”

Section: Discussionmentioning

confidence: 99%

Role of healthcare practitioners in rotavirus disease awareness and vaccination – insights from a survey among caregivers

Benninghoff

Pereira

Vetter

2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

An online survey was designed to assess awareness and understanding of Rotavirus (RV) gastroenteritis (RVGE), and knowledge and attitudes towards RV vaccination in Germany, Poland, Turkey, Indonesia, the Philippines and Thailand. Survey participants (n = 1500) comprised parents, expectant parents and guardians of children ≤5 years of age who have sole or joint responsibility for health and well-being decisions relating to their child, who were recruited from an online panel and provided their consent for study participation. Participants from most countries had a high level of awareness of RV infections (mean: 82%) and of those aware of RV, a mean of 61% participants were aware that RV was the most common cause of GE, however the majority (mean: 59%) were unaware that nearly every child would be infected with RVGE by the age of 5 years. Healthcare professional (HCP) recommendation was identified as the key driver for participants seeking vaccination (48%-75% of participants stated this reason, with results differing by country) followed by availability of RV vaccine in the national immunization program. Despite a high level of awareness of RVGE among participants, fostering knowledge regarding the difficulty of RVGE prevention, the risk of RV contraction and the associated serious consequences like dehydration is imperative to improve RV vaccination uptake. HCPs, being the primary influence on participants' decision on vaccination, are best suited to bridge existing knowledge gaps and recommend parents to vaccinate their children against RVGE.

show abstract

“…We have been able to provide overviews of full immunization programs developed using portfolio models. Examples include: showing the cost offsets and health gains of different dosing schemes using different vaccines for the same indication under a constrained budget (rotavirus vaccination) [41]; prioritising different intervention types to manage paediatric infections, and malaria [42,44]; demonstrating the benefit of child vaccination for working mothers with evidence of reduced work absenteeism [87]; improving QoC with vaccination and translating this into cost gains while maintaining QoC [50,60]; estimating the best combination of vaccination and screening to maximise cervical cancer reduction under a fixed budget [40]; and showing that extra budget does not guarantee substantial health gain in aging adults from PCV and/or influenza vaccination [43].…”

Section: Discussionmentioning

confidence: 99%

How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future

Standaert

Sauboin

DeAntonio³

et al. 2020

Journal of Market Access & Health Policy

Self Cite

View full text Add to dashboard Cite

Background:Cost-effectiveness analysis (CEA) is the economic analysis method most commonly applied today in the context of replacing one treatment with a new one in a developed healthcare system to improve efficiency. CEA is often requested by local healthcare decisionmakers to grant reimbursement.New preventative interventions, such as new vaccines, may however have much wider benefits inside and outside healthcare, when compared with treatment. These additional benefits include externalities on indirect clinical impact, reallocation of specific healthcare resources, improved quality of care, better productivity, better disease control, better fiscal revenues, and others. But these effects are sometimes difficult to integrate into a meaningful CEA result. They may appear as specific benefits for specific stakeholders, other than the stakeholders in healthcare.Objective: Based on a historical view about the application of economic assessments for vaccines our objective has been to make the inventory of who was/is interested in knowing the economic value of vaccines, in what those different stakeholders are likely to see the benefit from their perspective and how were/are we able to measure those benefits and to report them well. Results: The historical view disclosed a limited interest in the economic assessment of vaccines at start, more than 50 years ago, that was comparable to the assessment of looking for more efficiency in new industries through optimization exercises. Today, we are exposed to a very rich panoply of different stakeholders (n= 16). They have their specific interest in many different facets of the vaccine benefit of which some are well known in the conventional economic analysis (n=9), but most outcomes are hidden and not enough evaluated and reported (n=26). Meanwhile we discovered that many different methods of evaluation have been explored to facilitate the measurement and reporting of the benefits (n=18). Conclusion: Our recommendation for future economic evaluations of new vaccines is therefore to find the right combination among the three entities of stakeholder type selection, outcome measure of interest for each stakeholder, and the right method to apply. We present at the end examples that illustrate how successful this approach can be.

show abstract

Preferences for vaccines against children’s diarrheal illness among mothers in Poland and Hungary

Abstract: Polish and Hungarian working mothers are more likely to vaccinate children against diarrheal illness than non-working mothers.

Cited by 14 publications

References 11 publications

Preferences for herpes zoster vaccination among adults aged 50 years and older in the United States: results from a discrete choice experiment

Preferences for herpes zoster vaccination among adults aged 50 years and older in the United States: results from a discrete choice experiment

Role of healthcare practitioners in rotavirus disease awareness and vaccination – insights from a survey among caregivers

How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future

Contact Info

Product

Resources

About